Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Deepu Madduri: An Emerging CAR T-Cell Therapy for Myeloma

December 30, 2021

Deepu Madduri, MD, discusses findings from the CARTITUDE-1 trial, in which the new CAR T-cell therapy candidate led to a 100% response rate and high rates of minimal residual disease negativity in patients with relapsed/refractory multiple myeloma.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals